Atyr Pharma Inc (NASDAQ: ATYR)’s stock price has increased by 10.23 compared to its previous closing price of 3.42. However, the company has seen a 19.68% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-12 that SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine).
Is It Worth Investing in Atyr Pharma Inc (NASDAQ: ATYR) Right Now?
Additionally, the 36-month beta value for ATYR is 1.10. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ATYR is 81.96M and currently, short sellers hold a 3.56% ratio of that float. The average trading volume of ATYR on December 27, 2024 was 1.00M shares.
ATYR’s Market Performance
ATYR stock saw an increase of 19.68% in the past week, with a monthly gain of 20.83% and a quarterly increase of 116.67%. The volatility ratio for the week is 7.67%, and the volatility levels for the last 30 days are 7.48% for Atyr Pharma Inc (ATYR). The simple moving average for the last 20 days is 13.86% for ATYR stock, with a simple moving average of 74.57% for the last 200 days.
Analysts’ Opinion of ATYR
Many brokerage firms have already submitted their reports for ATYR stocks, with Wells Fargo repeating the rating for ATYR by listing it as a “Overweight.” The predicted price for ATYR in the upcoming period, according to Wells Fargo is $17 based on the research report published on October 04, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ATYR reach a price target of $9. The rating they have provided for ATYR stocks is “Buy” according to the report published on September 05th, 2024.
ATYR Trading at 17.44% from the 50-Day Moving Average
After a stumble in the market that brought ATYR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.79% of loss for the given period.
Volatility was left at 7.48%, however, over the last 30 days, the volatility rate increased by 7.67%, as shares surge +14.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.09% upper at present.
During the last 5 trading sessions, ATYR rose by +19.68%, which changed the moving average for the period of 200-days by +132.72% in comparison to the 20-day moving average, which settled at $3.31. In addition, Atyr Pharma Inc saw 167.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATYR starting from SCHIMMEL PAUL, who purchase 52,300 shares at the price of $1.93 back on Jul 24 ’24. After this action, SCHIMMEL PAUL now owns 413,023 shares of Atyr Pharma Inc, valued at $101,038 using the latest closing price.
SCHIMMEL PAUL, the Director of Atyr Pharma Inc, purchase 41,052 shares at $1.74 during a trade that took place back on Jul 22 ’24, which means that SCHIMMEL PAUL is holding 354,075 shares at $71,500 based on the most recent closing price.
Stock Fundamentals for ATYR
Current profitability levels for the company are sitting at:
- -289.59 for the present operating margin
- -5.64 for the gross margin
The net margin for Atyr Pharma Inc stands at -271.56. The total capital return value is set at -0.88. Equity return is now at value -77.96, with -58.90 for asset returns.
Currently, EBITDA for the company is -52.18 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 1355.64. The receivables turnover for the company is 0.13for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.41.
Conclusion
In conclusion, Atyr Pharma Inc (ATYR) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
